Credit score: Cell Reviews Medication (2025). DOI: 10.1016/j.xcrm.2025.102423
Researchers at The College of Texas MD Anderson Most cancers Middle, in collaboration with BostonGene, carried out the most important and most complete molecular evaluation of renal medullary carcinoma (RMC), a uncommon and aggressive type of kidney most cancers, resulting in the identification of TROP2 as a promising therapeutic goal.
Key discovery and significance
By evaluating 25 affected person samples, the researchers recognized overexpression of TROP2 and several other different cell-surface proteins in RMC, in addition to upregulation of the Hippo pathway. These findings led to the exploration of sacituzumab govitecan, a TROP2-targeted antibody-drug conjugate.
The work is revealed within the journal Cell Reviews Medication.
In a small cohort of 4 closely pretreated RMC sufferers, sacituzumab govitecan resulted in a single partial response and two sufferers with secure illness, with a median progression-free survival of two.9 months.
“Identifying TROP2 as a therapeutic target in renal medullary carcinoma marks a pivotal step toward precision treatment for one of the most aggressive and underserved cancers,” stated principal investigator Pavlos Msaouel, M.D., Ph.D., affiliate professor of Genitourinary Medical Oncology.
Future remedy implications
Renal medullary carcinoma is a fast-moving, treatment-resistant kidney most cancers primarily affecting younger people with sickle cell trait, highlighting the pressing want to grasp its molecular foundation to information therapeutic growth.
This research, which additionally characterised the RMC tumor microenvironment, helps additional investigation of medicine concentrating on TROP2 as remedy choices for this affected person inhabitants.
Extra info:
Identification of Therapeutic Targets for Renal Medullary Carcinoma through Built-in Genomic and Transcriptomic Profiling, Cell Reviews Medication (2025). DOI: 10.1016/j.xcrm.2025.102423. www.cell.com/cell-reports-medi … 2666-3791(25)00496-3
Offered by
College of Texas MD Anderson Most cancers Middle
Quotation:
Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic goal (2025, October 30)
retrieved 30 October 2025
from https://medicalxpress.com/information/2025-10-molecular-profiling-renal-medullary-carcinoma.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
